Table 1 Demographic information of study groups with clinical characteristics medication data for the schizophrenia group.
From: Reduced temporal variability of cortical excitation/inhibition ratio in schizophrenia
Variable | SZ (n = 30) | HC (n = 31) | Statistics | p-value |
|---|---|---|---|---|
Sex | 11F/19M | 13F/18M | \({\chi }^{2}\) = 0.1773 | p = 0.6737 |
Age | 33.07 ± 9.73 | 33.06 ± 10.31 | t = −0.0008 | p = 0.9993 |
Years in education | 16 [8; 18] | 16 [12; 18] | z = 1.0439 | p = 0.2965 |
Illness duration | 8.17 ± 8.57 | |||
CPZ equivalent dose | 394.16 ± 346.01 | |||
PANSS total score | 60.63 ± 17.74 | |||
PANSS general subscore | 30.10 ± 9.05 | |||
PANSS negative subscore | 15.90 ± 5.70 | |||
PANSS positive subscore | 14.63 ± 5.12 | |||
CPZ equivalent dose | 394.16 ± 346.01 |
Medication information (SZ group) | ||||
|---|---|---|---|---|
Medication name | n (mean dose ± SD mg) | Medication type | ||
Quetiapine | 3 (500 ± 285 mg) | antipsychotics | ||
Risperidone | 1 (2 mg) | |||
Flupentixol decanoate | 1 (20 mg) | |||
Clozapine | 13 (135 ± 132 mg) | |||
Haloperidol | 3 (3.75 ± 1.1 mg) | |||
Olanzapine | 4 (8.125 ± 2.4 mg) | |||
Amisulpride | 5 (430 ± 338 mg) | |||
Aripiprazole | 8 (16.875 ± 5.3 mg) | |||
Lithium | 5 (850 ± 224 mg) | Mood stabilizers | ||
Valproate | 2 (950 ± 71 mg) | |||
Lamotrigine | 1 (200 mg) | |||
Clonazepam | 9 (1.5 ± 0.9 mg) | Benzodiazepines | ||
Alprazolam | 1 (0.5 mg) | |||
Paroxetine | 1 (20 mg) | Antidepressants | ||
Sertraline | 1 (50 mg) | |||
Citalopram | 1 (20 mg) | |||
